Disclaimer.. the target mentioned is provisional as i dont have the lsp as yet to find the pivot in the point and figure chart
disclaimer... invested not an investing/trading recommendation the potential reversal zone of the bearish bar is supposed to be the end of the wave 3
Disclaimer..not an investing/trading recommendation
Disclaimer... interesting scrips.. not currently invested, started tracking the company and the stock price action recently
Disclaimer.. not invested, tracking.. not an investing/trading recommendation
on wave 4 correction after hyper extended wave 3 Disclaimer..not invested, tracking this diversified infra theme not an investing/trading recommendation
Disclaimer.... invested, will reaccumulate lower at expected supports not an investing/trading recommendation
volumes declining on the fall, might be a spring, here or a selling climax Disclaimer... not invested, watching the price action
Disclaimer... plannning to enter after breakout not an investing/trading recommendation
Disclaimer.. not an investing/trading recommendation
resistances as mentioned... Disclaimer.. not an investing/trading recommendation
Disclaimer.. not an investing /trading recommendation invested..
Delay in greenfield expansion at the Kakinada facility and slower de-bottlenecking at the existing Hyderabad and Vizag facilities are some lingering issues that are unlikely to get sorted out anytime soon.. Serious doubt about any topline growth possibility to write home about... although with the lifting of import alert for Vizag and recent clearance...
BLS international- After coming back on the growth visibility with a new UK contract which is the largest of all the contracts win by the company till date, and the punjab woes kind of soothed after the news that the punjab gov has allocated the receivables due to bls in the yearly budget and of that 30cr has already come in april… the correction i was waiting...
Disclaimer... invested... Not an investing/trading recommendation
Torrent pharma filed 13 ANDAs in FY18 ,currently 46 ANDAs are pending for approval including six from Biopharma.,Overall it has 51 filings pending with US FDA including 5 tentative approvals,plans to file 15-20 ANDAs in the US in FY19 and expects eight to 10 approvals. Launched Hydrocodonsuppository from Biopharma portfolio in 4QFY18, To launch 8-9 products in...